Merck KGaA Investor Presentation — May 2022

Document content

Classification: CONFIDENTIAL

May12, 2022Merck Q12022 results

Presentation for the mediaoff to a strong start

Classification: CONFIDENTIAL

Merck Q1 2022 Results Presentation | May 12, 2022 2Cautionary Note Regarding Forward-Looking Statements andfinancial indicators

This communication may include “forward -looking statements.” Statements that include words such as “anticipate,” “expect,” “shou ld,” “would,” “intend,” “plan,” “project,” “seek,”

“believe,” “will,” and other words of similar meaning in connection with future events or future operating or financial performa nce are often used to identify forward -looking statements.

All statements in this communication, other than those relating to historical information or current conditions, are forward -looking statements. We intend these forward- looking

statements to be covered by the safe harbor provisions for forward -looking statements in the Private Securities Litigation Refor m Act of 1995. These forward- looking statements are

subject to a number of risks and uncertainties, many of which are beyond control of Merck KGaA , Darmstadt, Germany, which could cause actual results to differ materially from such

Risks anduncertainties include, butarenotlimited to:therisks ofmore restrictive regulatory requirements regarding drug pricing, reimbursement andapproval ;theriskofstricter

regulations forthemanufacture, testing andmarketing ofproducts ;theriskofdestabilization ofpolitical systems andtheestablishment oftrade barriers ;theriskofachanging

marketing environment formultiple sclerosis products intheEuropean Union; theriskofgreater competitive pressure duetobiosimilars ;therisks ofresearch anddevelopment ;the

risks ofdiscontinuing development projects andregulatory approval ofdeveloped medicines ;theriskofatemporary banonproducts/production facilities orofnon-registration of

products duetonon-compliance withquality standards; theriskofanimport banonproducts totheUnited States duetoanFDAwarning letter ;therisks ofdependency onsuppliers ;

risks duetoproduct -related crime andespionage; risks inrelation totheuseoffinancial instruments ;liquidity risks;counterparty risks;market risks;risks ofimpairment onbalance

sheet items ;risks from pension obligations ;risks from product -related andpatent lawdisputes ;risks from antitrust lawproceedings ;risks inhuman resources; risks from e-crime and

cyber attacks; risks duetofailure ofbusiness -critical information technology applications ortofailure ofdatacenter capacity ;environmental andsafety risks;unanticipated contract or

regulatory issues ;apotential downgrade intherating oftheindebtedness ofMerck KGaA ,Darmstadt, Germany ;downward pressure onthecommon stock price ofMerck KGaA ,